Curis Inc.

CRIS

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001108205

E

weakest fifth of 369 graded peers in healthcare

rank 369 of 369; percentile 100.0; sampling error 2.5 points; lower is stronger


A B C D E

E, the bear




Scoreboard	
Profitability	E percentile 98.6
Solvency	E percentile 97.4
Growth and financing	E percentile 89.2
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $20.0M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, short runway, distress not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 24, 2026 234 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$0.58 2026-11-12; market equity $1.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 24, 2026

We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 98.6						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	64.1%	(6.6%)	98.6	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 97.4					
Twelve-month failure probability	42.56%	0.08%	98.8	247	2026-06-30
Altman Z double-prime	(207.55)	(0.35)	98.3	744	2025-12-31
Net debt to EBITDA	not computable	1.82x			
required facts have no common fiscal period end					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	0.49x	2.95x	95.3	826	2025-12-31
Growth and financing, sleeve percentile 89.2					
Revenue growth, three-year compound	(2.4%)	10.1%	77.1	412	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(43.2%)	2.2%	97.7	694	2025-12-31
Net share issuance, one year	371.1%	2.5%	92.8	627	2026-03-20


Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 371.1%
Short runway	cash runway is 2.0 months
Distress	CHS probability 42.559752%; universe top-decile threshold 2.222209%

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
364	Coherus Oncology, Inc. (CHRS)	98.6	E	dilution, short runway
365	Atara Biotherapeutics, Inc. (ATRA)	98.9	E	dilution, short runway, distress
366	HCW Biologics Inc. (HCWB)	99.2	E	dilution, short runway, late filer, degenerate inputs, fortress balance sheet
367	PAVmed Inc. (PAVM)	99.5	E	dilution, short runway, degenerate inputs
368	Inovio Pharmaceuticals, Inc. (INO)	99.7	E	dilution, degenerate inputs, distress
369	Curis Inc. (CRIS)	100.0	E	dilution, short runway, distress

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-12 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(97.2%)	(1.9%)	0
Distance from 52-week high	(97.9%)	(30.8%)	1
EBIT to enterprise value	not computable	(1.9%)	
Free cash flow yield	(3,215.9%)	(1.0%)	0
Book value to price	3.93	0.28	98
Sales to price	7.90	0.29	99
Composite equity issuance, five years	221.2%	20.5%	91
Relative strength against the sector, log excess return	(3.74)	(0.19)	0

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$5.1M
Operating cash flow, four quarters	-$30.6M
Months of runway	2.0
Days since last periodic filing	91 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$170,133

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$7.6M	2025-12-31	2026-03-24	10-K	26-000043
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$27.2M	2025-12-31	2026-03-24	10-K	26-000043
3	assets	us-gaap:Assets	$20.0M	2025-12-31	2026-03-24	10-K	26-000043
4	assets	us-gaap:Assets	$41.3M	2024-12-31	2026-03-24	10-K	26-000043
5	current assets	us-gaap:AssetsCurrent	$6.9M	2025-12-31	2026-03-24	10-K	26-000043
6	current liabilities	us-gaap:LiabilitiesCurrent	$14.1M	2025-12-31	2026-03-24	10-K	26-000043
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.2B	2025-12-31	2026-03-24	10-K	26-000043
8	operating income	us-gaap:OperatingIncomeLoss	-$5.7M	2025-12-31	2026-03-24	10-K	26-000043
9	book equity	us-gaap:StockholdersEquity	$5.5M	2025-12-31	2026-03-24	10-K	26-000043
10	liabilities	us-gaap:Liabilities	$14.5M	2025-12-31	2026-03-24	10-K	26-000043
11	operating income	us-gaap:OperatingIncomeLoss	-$42.1M	2021-12-31	2023-03-13	10-K	23-000023
12	interest expense	us-gaap:InterestExpense	$0	2021-12-31	2022-02-24	10-K	22-000002
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$9.4M	2025-12-31	2026-03-24	10-K	26-000043
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10.9M	2024-12-31	2026-03-24	10-K	26-000043
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10.0M	2023-12-31	2025-03-31	10-K	25-000031
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10.2M	2022-12-31	2024-02-08	10-K	24-000010
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$38.4M	2023-12-31	2025-03-31	10-K	25-000031
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2023-12-31	2024-02-08	10-K	24-000010

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$54.3M	2022-12-31	2024-02-08	10-K	24-000010
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$416,000	2022-12-31	2024-02-08	10-K	24-000010
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$37.6M	2021-12-31	2023-03-13	10-K	23-000023
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2021-12-31	2023-03-13	10-K	23-000023
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$25.7M	2020-12-31	2022-02-24	10-K	22-000002
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$677,000	2020-12-31	2022-02-24	10-K	22-000002
25	assets	us-gaap:Assets	$77.3M	2023-12-31	2025-03-31	10-K	25-000031
26	assets	us-gaap:Assets	$108.8M	2022-12-31	2024-02-08	10-K	24-000010
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	39,978,693	2026-03-20	2026-03-24	10-K	26-000043
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,487,818	2025-03-27	2025-03-31	10-K	25-000031

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.